Loading organizations...
§ Private Profile · Vancouver, BC, Canada
Molecular You is a technology company.
Molecular You offers a comprehensive, science-backed health assessment to help make informed health decisions whether you're a healthcare provider or an individual looking to take control of your health.
Molecular You has raised $5.0M across 1 funding round.
Molecular You has raised $5.0M in total across 1 funding round.
Molecular You has raised $5.0M across 1 funding round. Most recently, it raised $5.0M Series A in August 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 1, 2025 | $5M Series A | David S. Vogel | VoLo Earth Ventures, Dynamic Leap | Announced |
Molecular You is a precision health technology company that provides advanced molecular analysis through a single blood test measuring over 250 biomarkers across 26+ health areas, including cardiovascular, metabolic, inflammatory, cognitive, and behavioral health[1][2][3][5]. It serves both individuals and healthcare providers (clinics in the US and Canada) by delivering AI-driven personalized reports, actionable lifestyle recommendations (diet, supplements, exercise), and progress tracking to enable predictive, preventative care and early disease risk detection, such as pre-diabetes, atherosclerosis, Alzheimer's, PCOS, and even stage 1 pancreatic cancer[1][2][3][4]. The platform uses proteomics, metabolomics, systems biology, and next-generation mass spectrometry (e.g., Multiple Reaction Monitoring for precise protein quantification) to offer holistic insights beyond traditional symptomatic diagnostics, with recent $5M Series A funding fueling growth[1][2][4].
Molecular You was founded in 2014 as a spin-off from Canada's Personalized Medicine Initiative in Vancouver, BC, with key leaders including Dr. Rob Fraser (PhD, Chief Scientific Officer, Co-Founder, and President) and Dr. Murdoc Khaleghi (Chief Medical Officer)[1][3][4]. The idea emerged from advancing molecular-level understanding for prevention and personalized care, leveraging peer-reviewed research in multi-omics to analyze interconnected biological pathways[1][3]. Early traction included scientific validation, real-world successes like detecting asymptomatic pancreatic cancer for life-saving intervention, and building a direct-to-consumer platform with at-home blood draws and digital dashboards[2][4].
Molecular You rides the explosive longevity and precision medicine wave, where investments doubled to $8.5B from 2023-2024, driven by AI-multiomics convergence for preventative care amid rising chronic diseases[2][4]. Timing aligns with post-pandemic demand for proactive health tools, as traditional diagnostics lag behind asymptomatic risks in complex conditions like autoimmune diseases and neurodegeneration[2][4]. Market forces favoring it include booming consumer wellness, clinician adoption for functional medicine, and global expansion (e.g., Asia via NKCL Bio partnership), influencing the ecosystem by setting standards for data-driven, personalized health and bridging DTC with clinical precision[1][4].
Molecular You is poised to scale with its $5M Series A (led by Voloridge Health), advancing to a next-gen assay measuring 800+ biomarkers and entering cancer diagnostics, alongside big data platforms for global reach[4]. Trends like AI-enhanced multi-omics, longevity tech, and personalized prevention will propel it, potentially evolving from biomarker leader to full precision medicine powerhouse amid ecosystem shifts toward root-cause interventions. This builds on its pioneering foundation, empowering proactive health at scale.
Molecular You has raised $5.0M in total across 1 funding round.
Molecular You's investors include David S. Vogel, VoLo Earth Ventures, Dynamic Leap.